Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for tough blood cancers: LP-118 trial launches

NCT ID NCT04771572

First seen May 06, 2026 · Last updated Jun 16, 2026 · Updated 7 times

Summary

This early-stage study tests a new oral drug, LP-118, in up to 100 adults with blood cancers like lymphoma, leukemia, or myeloma that returned or didn't respond to prior therapy. The main goals are to find the safest dose and see if the drug can shrink tumors or slow the disease. Participants take the drug once daily, and researchers monitor side effects and how the body processes the medication.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Cincinnati Children's Hospital Medical Center

    RECRUITING

    Cincinnati, Ohio, 45229, United States

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

  • The Ohio State University

    RECRUITING

    Columbus, Ohio, 43210, United States

  • University of Chicago

    RECRUITING

    Chicago, Illinois, 60637, United States

  • University of Cincinnati

    RECRUITING

    Cincinnati, Ohio, 45229, United States

  • University of North Carolina

    RECRUITING

    Chapel Hill, North Carolina, 27514, United States

  • University of Utah

    RECRUITING

    Salt Lake City, Utah, 84112, United States

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia B-cell chronic lymphocytic leukemia hematopoietic and lymphoid system neoplasm myelodysplastic/myeloproliferative disease non-Hodgkin lymphoma plasma cell myeloma Precursor Cell Lymphoblastic Leukemia-Lymphoma primary myelofibrosis Recurrence T-cell prolymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.